Alpine Immune Sciences, Inc. (ALPN)

64.43 -0.03 (-0.05%) At close: 04:00PM EDT

Alpine Immune Sciences, Inc.

188 East Blaine Street
Suite 200
Seattle, WA 98102
United States
206 788 4545
https://www.alpineimmunesciences.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 142

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Mitchell H. Gold M.D.	Executive Chairman & CEO	778.2k	N/A	1968
Dr. Stanford Peng M.D., Ph.D.	President and Head of Research & Development	751.2k	N/A	1971
Mr. Paul Rickey	Senior VP, CFO, Treasurer & Secretary	577.1k	N/A	1979

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.

Corporate governance

Alpine Immune Sciences, Inc.’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 7; Board: 8; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.